Celcuity (NASDAQ:CELC) Given New $125.00 Price Target at Stifel Nicolaus

Celcuity (NASDAQ:CELC) had its price objective increased by Stifel Nicolaus from $115.00 to $125.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently issued reports on CELC. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 target price on shares of Celcuity in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Wolfe Research restated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a report on Thursday, March 12th. Jefferies Financial Group upped their price objective on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, Wells Fargo & Company assumed coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $109.88.

Celcuity Stock Performance

NASDAQ CELC opened at $114.81 on Thursday. The firm’s fifty day moving average price is $109.51 and its two-hundred day moving average price is $90.44. The stock has a market cap of $5.31 billion, a PE ratio of -30.29 and a beta of 0.38. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $120.32. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, equities analysts expect that Celcuity will post -2.62 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 15.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently made changes to their positions in CELC. Vanguard Group Inc. increased its position in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after buying an additional 391,262 shares during the period. New York State Common Retirement Fund raised its stake in Celcuity by 68.0% during the third quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock worth $2,357,000 after buying an additional 19,313 shares during the last quarter. Atle Fund Management AB acquired a new position in Celcuity in the third quarter valued at $1,836,000. Candriam S.C.A. lifted its holdings in Celcuity by 48.3% in the third quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock valued at $19,312,000 after buying an additional 127,348 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in Celcuity by 2,142.0% during the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock valued at $772,000 after acquiring an additional 14,930 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $125 and maintained a “buy” rating, signaling increased analyst confidence and providing fresh upside for investors. Article Title
• Positive Sentiment: Needham & Company reaffirmed its “buy” rating and a $122 price target, reinforcing the broker-dealer support that can sustain upward momentum. Benzinga Street Insider
• Positive Sentiment: Q4 2025 results beat estimates: EPS of ($0.73) vs. consensus ($1.06) — the miss narrowed and the beat reduces near-term downside from earnings concerns. Market commentary and the company release came with the results. MarketBeat Earnings
• Positive Sentiment: Management highlighted a potential ~$2.5B annual peak revenue opportunity for gedatolisib and ongoing pivotal milestones/commercial launch preparations — a high commercial upside that supports premium valuations if regulatory and launch execution succeed. MSN Article
• Neutral Sentiment: Investors can review the full Q4 call transcript and highlights for more color on development timelines, cash runway and next catalysts (transcript and call recording available). Seeking Alpha Transcript Yahoo Highlights
• Neutral Sentiment: Corporate release summarizing Q4 and full-year 2025 results and the company update (official details on financials and program status). GlobeNewswire
• Positive Sentiment: Press coverage noting that Celcuity’s breast cancer drug is approaching regulatory milestones/possible approval has likely boosted optimism around near-term value realization. Investing.com
• Negative Sentiment: Company remains unprofitable (negative EPS) and carries leverage (reported debt-to-equity and negative PE), risks that could limit gains if clinical or regulatory setbacks occur. Press Release PDF

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.